Augustine Therapeutics

Augustine Therapeutics focuses on the discovery and development of innovative medicines to benefit patients suffering from Charcot-Marie-Tooth disease (CMT) and other peripheral neuropathies, neurodegenerative and cardiometabolic disorders. The company is rooted in the ground-breaking research at VIB and KU Leuven and supported by Asabys Partners, Eli Lilly and Company, V-Bio Ventures, PMV, AdBio Partners, VIB, Gemma Frisius Fund and CMT Research Foundation.